Pesquisar
Biogen Inc
BIIBAdicionar à lista de desejos
199.590USD
+2.400+1.22%
Fechamento 06/24, 16:00（ET）Cotações atrasadas em 15 min
29.47BValor de mercado
21.35P/L TTM
Mais detalhes de Biogen Inc Empresa
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Informações de Biogen Inc
Código da empresaBIIB
Nome da EmpresaBiogen Inc
Data de listagemSep 17, 1991
CEOViehbacher (Christopher A)
Número de funcionários7605
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 17
Endereço225 Binney Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Telefone17814642000
Sitehttps://www.biogen.com/
Código da empresaBIIB
Data de listagemSep 17, 1991
CEOViehbacher (Christopher A)
Executivos da empresa Biogen Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.89K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
27.84K
-4.94%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.10K
+20.79%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
19.75K
+0.69%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
16.08K
+30.17%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.82K
+11.74%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.89K
+16.92%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
8.04K
-0.01%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
6.45K
+31.09%
Dr. Adam James Keeney, Ph.D.
Dr. Adam James Keeney, Ph.D.
Executive Vice President, Head of Corporate Development
Executive Vice President, Head of Corporate Development
6.37K
+7.60%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.89K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
27.84K
-4.94%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.10K
+20.79%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
19.75K
+0.69%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
16.08K
+30.17%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.82K
+11.74%
Perguntas frequentes
Quem são os cinco principais acionistas de Biogen Inc?
Os cinco principais acionistas de Biogen Inc são: Ms. Susan H. Alexander, Esq., J.D.
Quantas instituições possuem ações da Biogen Inc (BIIB)?
Em 2026Q1, 2085 instituições possuíam ações da Biogen Inc, com valor de mercado aproximado de 144.76M, representando 98.05% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -3983853.00.
Qual é a maior fonte de receita da Biogen Inc?
Em 2026Q1, o segmento de negócios Spinal Muscular Atrophy-SPINRAZA gerou a maior receita para Biogen Inc, totalizando 2.15B e representando 21.78% da receita total.
